1. Home
  2. BIO vs IBRX Comparison

BIO vs IBRX Comparison

Compare BIO & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bio-Rad Laboratories Inc.

BIO

Bio-Rad Laboratories Inc.

SELL

Current Price

$364.61

Market Cap

10.1B

Sector

Industrials

ML Signal

SELL

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

SELL

Current Price

$10.16

Market Cap

8.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BIO
IBRX
Founded
1952
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1B
8.2B
IPO Year
1994
2015

Fundamental Metrics

Financial Performance
Metric
BIO
IBRX
Price
$364.61
$10.16
Analyst Decision
Hold
Strong Buy
Analyst Count
3
4
Target Price
★ $328.33
$12.75
AVG Volume (30 Days)
256.4K
★ 11.3M
Earning Date
10-29-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 142.61
38.71
EPS
N/A
★ N/A
Revenue
★ $2,583,200,000.00
$113,288,000.00
Revenue This Year
N/A
$99.26
Revenue Next Year
$2.13
$101.32
P/E Ratio
★ N/A
N/A
Revenue Growth
0.65
★ 668.31
52 Week Low
$236.73
$1.95
52 Week High
$396.23
$12.43

Technical Indicators

Market Signals
Indicator
BIO
IBRX
Relative Strength Index (RSI) 45.64 62.49
Support Level $358.85 $6.68
Resistance Level $392.81 $10.82
Average True Range (ATR) 12.52 0.59
MACD -2.22 0.13
Stochastic Oscillator 30.27 70.90

Price Performance

Historical Comparison
BIO
IBRX

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Share on Social Networks: